Original article
The relationship of weight change to changes in blood pressure, serum uric acid, cholesterol and glucose in the treatment of hypertension

https://doi.org/10.1016/0021-9681(85)90073-6Get rights and content

Abstract

In the Hypertension Detection and Follow-up Program (HDFP), elevated blood pressure (BP) was treated by rigorous, stepped care (SC) therapy among half the participants, while the other half were referred to usual sources of care (referred care, RC). There was no program to reduce weight, however, some participants changed weight voluntarily over the first 2yr, providing an opportunity to examine the role of weight change in the development of diuretic-induced hyperuricemia, hyperglycemia and hypercholesterolemia. There was a stepwise progression from decreased glucose, uric acid and cholesterol concentrations, and BP associated with maximum weight loss to increased values with maximum weight gain. In SC, systolic BP declined by 22.4% among weight-losers and by 17.1% among weight-gainers; in RC, it was 14.4 and 8.1%, respectively. The pattern in diastolic blood pressure and weight change was similar but not as marked. These findings suggest the potential importance of weight loss in enhancing effectiveness of antihypertensive drug treatment and attenuating increases in glucose, uric acid, and cholesterol associated with diuretic treatment of hypertension. The weight change analyses are based on postrandomization observations and do not reflect experimental changes.

References (13)

There are more references available in the full text version of this article.

Cited by (35)

  • The metabolic syndrome: A critical appraisal based on the CUORE epidemiologic study

    2009, Preventive Medicine
    Citation Excerpt :

    However, other investigations – e.g., the Framingham Offspring and CARDIA studies (Wilson et al., 1999; Lloyd-Jones et al., 2007) – reported both cross-sectional and prospective data on this matter concordant with CUORE findings. Concordant data are also available from clinical trials on the relation of weight change to change the other MetS traits (Farinaro et al., 1977; Heyden et al., 1985; Stamler et al., 1997; Diabetes Prevention Program Research Group, 2002). Such findings prevail with use of either BMI (with its limitations), or waist circumference (WC), or both, as in the CUORE Project.

View all citing articles on Scopus

Research upon which this publication is based was performed pursuant to Contract Nos. NO1-HV-12433-42; NO1-HV-22931, 37–39, 45; NO1-HV-32933; NO1-HV-72915 and NO1-HV-82915 with the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services.

View full text